Sankyo Co. Newsletter
-
Daiichi Sankyo Company, Limited (DSNKY) Discusses ESMO 2025 Highlights With Focus on Key Breast Cancer Trial Data and Regulatory Submissions Transcript
21 Oct 2025 21:35 GMT
… 'll now start Daiichi Sankyo's ESMO 2025 highlights …
-
AstraZeneca, Daiichi Sankyo announce Enhertu demonstrated improvement in IDFS
19 Oct 2025 23:56 GMT
AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) announced positive results from …
-
ADC, Bispecifics and Kinase Blockers Steal the Spotlight at ESMO 2025 in Berlin
22 Oct 2025 15:19 GMT
… is AstraZeneca with its Daiichi Sankyo–partnered ADC Datroway. At ESMO …
-
New Drugs Show Promise In Tough-To-Treat Cancers
22 Oct 2025 16:22 GMT
… deruxtecan, co-developed with Daiichi Sankyo. A phase II/III …
-
AstraZeneca Bolsters Oncology with £1.2 Billion Fusion Buyout Amid UK Growth
22 Oct 2025 12:48 GMT
… it acquired through its Daiichi Sankyo partnership in 2019.
The agreement …
-
REJOICE─Ovarian01 phase 2/3 trial of raludotatug deruxtecan demonstrated clinically meaningful response rates in patients with recurrent platinum─resistant ovarian, primary peritoneal or fallopian tube cancer
22 Oct 2025 07:46 GMT
… ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC … -based cleavable linkers.
Daiichi Sankyo and Merck (known as … except in Japan where Daiichi Sankyo will maintain exclusive rights. … developed by Daiichi Sankyo.
The second Daiichi Sankyo ADC platform …
-
Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib
22 Oct 2025 07:57 GMT
… personal fees from AstraZeneca, Daiichi Sankyo, Pfizer, Lilly, Genentech, Regeneron, Johnson …
-
[ESMO 2025] Hanmi Pharma targets solid tumors with ‘EZH1/2 dual inhibitor’
22 Oct 2025 04:51 GMT
… lymphoma and rare cancers. Daiichi Sankyo's Valemetostat is also …
-
‘We need to pick a lane’: Lilly oncology president weighs in on FDA cancer drug policies
22 Oct 2025 04:02 GMT
… past weekend, AstraZeneca and Daiichi Sankyo’s Datroway showed in the …
-
The Lancet: Antidepressants vary widely in their physical side effects, highlighting the need for personalised prescribing, says major meta-analysis
22 Oct 2025 03:31 GMT
… fees from Boehringer Ingelheim,
Daiichi Sankyo, DT Axis, Micron, Shionogi, SONY …